Biontech SE
BNTX104.800USD
-0.290-0.28%
終値 06/25, 16:00（ET）15分遅れの株価
25.19B時価総額
損失額直近12ヶ月PER
詳細情報 Biontech SE 企業名
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
企業情報
企業コードBNTX
会社名Biontech SE
上場日Oct 10, 2019
設立日2019
最高経営責任者「CEO」Prof. Ugur Sahin, M.D.
従業員数6772
証券種類Depository Receipt
決算期末Oct 10
本社所在地An der Goldgrube 12
都市MAINZ
証券取引所NASDAQ Global Select Consolidated
国Germany
郵便番号55131
電話番号4949613190840
ウェブサイトhttps://www.biontech.com/
企業コードBNTX
上場日Oct 10, 2019
設立日2019
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
収益内訳
通貨: EUR更新時刻: Wed, Mar 12
通貨: EUR更新時刻: Wed, Mar 12
FY2019
FY2018
FY2017
事業別EUR
会社名
収益
比率
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
データなし
事業別
地域別
事業別EUR
会社名
収益
比率
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
株主
更新時刻: Thu, May 15
更新時刻: Thu, May 15
株主統計
種類
株主統計
株主統計
比率
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.39%
Fidelity Management & Research Company LLC
2.48%
Flossbach von Storch AG
1.77%
Other
33.30%
株主統計
株主統計
比率
AT Impf GmbH
42.37%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.39%
Fidelity Management & Research Company LLC
2.48%
Flossbach von Storch AG
1.77%
Other
33.30%
種類
株主統計
比率
Corporation
60.58%
Investment Advisor
15.20%
Investment Advisor/Hedge Fund
3.62%
Individual Investor
2.11%
Hedge Fund
1.21%
Research Firm
1.16%
Sovereign Wealth Fund
0.75%
Pension Fund
0.20%
Bank and Trust
0.17%
Other
15.00%
機関投資家保有株
更新時刻: Sun, Jan 19
更新時刻: Sun, Jan 19
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q1
834
205.89M
85.65%
+5.68M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
2022Q4
937
198.79M
81.74%
-3.98M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
AT Impf GmbH
101.85M
42.44%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.43M
16.85%
-7.37K
-0.02%
Dec 31, 2024
Baillie Gifford & Co.
8.22M
3.43%
-87.49K
-1.05%
Dec 31, 2024
Fidelity Management & Research Company LLC
6.45M
2.69%
+1.27M
+24.48%
Dec 31, 2024
Flossbach von Storch AG
4.41M
1.84%
+47.24K
+1.08%
Dec 31, 2024
PRIMECAP Management Company
4.30M
1.79%
-220.70K
-4.89%
Dec 31, 2024
Pfizer Inc
3.66M
1.52%
+3.66M
--
Dec 31, 2024
Sahin (Ugur MD)
2.77M
1.16%
+1.92M
+224.09%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Dec 31, 2024
Capital International Investors
1.42M
0.59%
+394.43K
+38.63%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Fri, Jun 6
更新時刻: Fri, Jun 6
銘柄名
比率
Langar Global HealthTech ETF
7.85%
iShares Genomics Immunology and Healthcare ETF
3.76%
Global X Genomics & Biotechnology ETF
3.1%
First Trust NYSE Arca Biotechnology Index Fund
3.04%
Franklin Genomic Advancements ETF
2.7%
VanEck Biotech ETF
2.5%
WisdomTree BioRevolution Fund
1.57%
iShares Biotechnology ETF
1.49%
Virtus LifeSci Biotech Products ETF
1.39%
Invesco Nasdaq Biotechnology ETF
0.99%
詳細を見る
Langar Global HealthTech ETF
比率7.85%
iShares Genomics Immunology and Healthcare ETF
比率3.76%
Global X Genomics & Biotechnology ETF
比率3.1%
First Trust NYSE Arca Biotechnology Index Fund
比率3.04%
Franklin Genomic Advancements ETF
比率2.7%
VanEck Biotech ETF
比率2.5%
WisdomTree BioRevolution Fund
比率1.57%
iShares Biotechnology ETF
比率1.49%
Virtus LifeSci Biotech Products ETF
比率1.39%
Invesco Nasdaq Biotechnology ETF
比率0.99%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
